All In Biotech

Drug Trial Radar · NCT07559175

A Study to Evaluate Safety and Explore Efficacy of New Lipase NHS7108 in Adult Participants With Exocrine Pancreatic Insufficiency.

A Phase 2a, Randomized, Open-Label, Active-Controlled, Crossover Study to Evaluate Safety and Explore Efficacy of Different Doses of New Lipase NHS7108 Administered Orally in Participants With Exocrine Pancreatic Insufficiency- EPIC

Last checked: Nov 19, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

66

Planned (sponsor's estimate)

Start

Oct 2026

Primary completion

Jun 2027

Study completion Sep 2027

Sponsor

Sponsor type
Industry
Collaborators
Parexel
First posted
Apr 30, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to measure the safety and explore the efficacy of 4 different doses of the new lipase NHS7108 in participants with EPI. In this study, all participants will take NHS7108 daily for 14 days and a matching dose of standard-of-care, pancrelipase (Zenpep®) for 14 days according to Treatment Sequence assignment. Both NHS7108 and Zenpep® are oral capsules that will be taken with each of the daily 3 meals and 2 snacks. Participants will interrupt all of their usual pancrelipase/pancreatin treatment for up to 8 days during screening and for the entire 2 treatment periods, where participants will take either the new lipase NHS7108 or a matching dose of the standard-of-care pancrelipase (Zenpep®). Participants will be asked to stay in a setting that allows controlled diet and 72-hour stool collection for approximately 7 days during the screening period and again for approximately 7 days at the end of each treatment period. During these 3 supervised periods, participants will receive a standardized diet with a predefined amount of fat and protein, stools will be collected in special containers and during the last day of the treatment period, blood samples will be obtained to measure fat absorption. These are essential to ensure valid assessment of participants' fat and protein absorption. Outside the 3 supervised periods, participants will be provided with guidelines and recommendations to create their own home-controlled meals and snacks according to their preferences for the remainder of the study duration. Number of Participants: The aim is to have 56 participants completing the study. Assuming approximately 14% drop-out rate, approximately 66 participants will be randomized to study intervention. Study Arms and Duration: The total study duration for each participant will be about 100 days (approximately 14 weeks), including: * A screening period of up to approximately 28 days (might be extended up to a total of 56 days) prior to the first dose administration. * A crossover treatment period (2 treatment periods: approximately 14 days each, with no washout in between). For each treatment period, study intervention will be administered 5 times a day (with 3 main meals and 2 snacks). After completion of Treatment Period 1, the participant will receive and start the new treatment for Treatment Period 2. * An end of treatment/early discontinuation visit within approximately 7 days of the last study intervention dose. * An end-of-study safety follow-up visit at 14 (±2) days after the last dose administration. Very low dose group: 10 mg NHS7108 (approximately 25,000 LU)/main meal and snack; 25,000 LU Zenpep/main meal and snack (50 mg NHS7108 \[approximately 125,000 LU\] per day; 125,000 LU Zenpep per day) Low dose group: 20 mg NHS7108 (approximately 50,000 LU)/main meal and 10 mg NHS7108 (approximately 25,000 LU)/snack; 50,000 LU Zenpep/main meal and 25,000 LU Zenpep/snack (80 mg NHS7108 \[approximately 200,000 LU\] per day; 200,000 LU Zenpep per day) Medium dose group: 40 mg NHS7108 (approximately 100,000 LU)/main meal and 20 mg (approximately 50,000 LU) NHS7108/snack; 100,000 LU Zenpep/main meal and 50,000 LU Zenpep/snack (160 mg \[approximately 400,000 LU\] NHS7108 per day; 400,000 LU Zenpep per day) High dose group: 60 mg NHS7108 (approximately 150,000 LU)/main meal and 30 mg NHS7108 (approximately 75,000 LU)/snack; 150,000 LU Zenpep/main meal and 75,000 LU Zenpep/snack (240 mg NHS7108 \[approximately 600,000 LU\] per day; 600,000 LU Zenpep per day). The dose for participants \< 60 kg who are assigned to the high dose group will need to be weight-adjusted to ensure that they receive no more than 10,000 LU/kg/day.

Conditions

  • Exocrine Pancreatic Insufficiency (EPI)
  • Cystic Fibrosis (CF)
  • Pancreatic Enzyme Abnormality
  • Pancreatic Diseases

Interventions

  • NHS7108Drug

    NHS7108 is the experimental drug. It is a recombinant, modified version of a triacylglycerol lipase enzyme derived from the bacteria Bacillus thermoamylovorans and produced by fermentation of recombinant Escherichia coli. Unit dose strength: 10 mg (approximately 25,000 LU) per capsule.

  • Zenpep®Drug

    Zenpep® is the active comparator. It is a combination of lipases, proteases, and amylases. Unit dose strength: 25,000 LU per capsule.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Objectives: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.Time frame: 14 days after NHS7108 Treatment
  2. Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.Time frame: At screening and end-of-study/safety follow-up visit. A brief symptom-directed physical examination may be performed at all other visits and at any time throughout the study, as clinically indicated.
  3. Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.Time frame: After 14 -day NHS7108 treatment
  4. Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.Time frame: After 14 -day NHS7108 treatment
  5. Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.Time frame: After 14 -day NHS7108 treatment
  6. Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.Time frame: After 14 -day NHS7108 treatment.
  7. Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.Time frame: After 14 -day NHS7108 treatment
  8. Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.Time frame: After 14 -day NHS7108 treatment
  9. Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.Time frame: 14-day after NHS7108 treatment
  10. Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.Time frame: 14-day after NHS7108 treatment
  11. Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.Time frame: 14-day after NHS7108 treatment
  12. Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.Time frame: 14-day after NHS7108 treatment
  13. Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.Time frame: 14-day after NHS7108 treatment
  14. Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.Time frame: 14-day after NHS7108 treatment
  15. Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.Time frame: 14-day after NHS7108 treatment
  16. Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.Time frame: 14 -day after NHS7108 treatment
  17. Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.Time frame: After 14 -day NHS7108 treatment
  18. Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.Time frame: After 14 -day NHS7108 treatment
  19. Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.Time frame: After 14 -day NHS7108 treatment
  20. Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.Time frame: After 14 -day NHS7108 treatment
  21. Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.Time frame: After 14 -day NHS7108 treatment
  22. Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.Time frame: Serum Beta-HCG pregnancy test (mIU/mL) (at screening) and urine pregnancy tests (at all other timepoints) as needed for women of childbearing potential.
  23. Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safety.Time frame: Will be performed at screening in women with unconfirmed reproductive potential status only (to confirm postmenopausal state).
  24. Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safetyTime frame: 14 days after NHS7108 Treatment
  25. Primary Objective: Safety of different doses of NHS7108 administered daily for 14 days in participants with exocrine pancreatic insufficiency (EPI). Coefficient of nitrogen absorption (CNA) will be measured as part of safetyTime frame: After 14 days NHS7108 treatment

Locations

39 sites in 7 countries. Site status is shown where the registry gives one.

  • HonorHealth Research Institute

    Scottsdale, Arizona · Not yet recruiting

  • University of Arkansas for Medical Sciences Hospital - University

    Little Rock, Arkansas · Not yet recruiting

  • Keck Hospital of USC

    Los Angeles, California · Not yet recruiting

  • Cedars Sinai Medical Center - Inflammatory Bowel Disease Ctr

    Los Angeles, California · Not yet recruiting

  • Omnicure Clinical Research

    Doral, Florida · Not yet recruiting

  • Advent Health Medical Group

    Orlando, Florida · Not yet recruiting

  • Johnson County Clin-Trials (JCCT)

    Lenexa, Kansas · Recruiting

  • Johns Hopkins Medicine - Pulmonary and Critical Care

    Baltimore, Maryland · Not yet recruiting

  • Billings Clinic Hospital - Public

    Billings, Montana · Not yet recruiting

  • University Hospitals Cleveland Medical Center/Rainbow Babies & Children's Hospital

    Cleveland, Ohio · Not yet recruiting

  • The Ohio State University College of Medicine (OSUCOM)

    Columbus, Ohio · Not yet recruiting

  • University of Oklahoma Health Sciences Center - Pediatrics Hospital - University

    Oklahoma City, Oklahoma · Not yet recruiting

  • Penn State Health

    Hershey, Pennsylvania · Recruiting

  • Vanderbilt University Medical Center - Pulmonary Hospital - University

    Nashville, Tennessee · Not yet recruiting

  • Medical Center Medconsult Pleven, Lovech branch

    Lovech, Bulgaria · Not yet recruiting

  • Medical Center Medconsult Pleven

    Pleven, Bulgaria · Not yet recruiting

  • MC Hipokrat-N - Gastroenterology

    Plovdiv, Bulgaria · Not yet recruiting

  • Medical Center Excelsior base 3

    Sofia, Bulgaria · Not yet recruiting

  • MH Egészségügyi Központ - Gasztroenterológiai Osztály

    Budapest, Hungary · Not yet recruiting

  • Semmelweis Egyetem. Sebeszeti, Transzplantacios es Gasztroenterologiai Klinika - Gasztroenterologiai Osztaly

    Budapest, Hungary · Recruiting

  • Szegedi Tudomanyegyetem Altalanos Orvostudomanyi Kar I. sz. Belgyogyaszati Klinika

    Csongrád, Hungary · Recruiting

  • Azienda Ospedaliero Universitaria Careggi - Gastroenterologia

    Florence, Italy · Not yet recruiting

  • IRCCS Ospedale San Raffaele - Endoscopia Biliopancreatica

    Milan, Italy · Not yet recruiting

  • Azienda Ospedaliera Universitaria Sant'Andrea

    Roma, Italy · Not yet recruiting

  • AOU Policlinico G. Rodolico - Ospedale San Marco - Broncopneumologia Pediatrica e Fibrosi Cistica Hospital - Public

    Catania, Catania, Italy · Not yet recruiting

  • Humanitas Research Hospital

    Rozzano, Lombardy, Italy · Not yet recruiting

  • Azienda Ospedaliero Universitaria Policlinico Gaetano Martino - Gastroenterologia Pediatrica e Fibrosi Cistica Academic / University Clinic

    Messina, Messina, Italy · Not yet recruiting

  • Bonifraterskie Centrum Medyczne Sp. z o.o. Oddzial w Lodzi, Szpital Zakonu Bonifratrow Sw. Jana Bozego w Lodzi - Dzial Endoskopi

    Lodz, Łódź Voivodeship, Poland · Not yet recruiting

  • WIP Warsaw IBD Point Profesor Kierkus

    Pomorskie, Warszawa, Poland · Not yet recruiting

  • Hospital Universitari Arnau de Vilanova de Lleida

    Lleida, Spain · Recruiting

  • H. General de Málaga - Endocrinología

    Málaga, Spain · Recruiting

  • Hospital Universitario y Politecnico La Fe - Neumología

    Valencia, Spain · Recruiting

  • Hospital Clinic De Barcelona - Cirug-ía General y Digestiva

    Madrid, Barcelona, Spain · Not yet recruiting

  • Hospital Universitario La Paz Hospital - University

    Madrid, Madrid, Spain · Not yet recruiting

  • Universidad de Murcia - Hospital Universitario Virgen de la Arrixaca (HUVA)

    Murcia, Murcia, Spain · Not yet recruiting

  • Greater Glasgow and Clyde

    Glasgow, United Kingdom · Not yet recruiting

  • The Newcastle Upon Tyne Hospitals NHS Foundation Trust - Royal Victoria Infirmary

    Newcastle upon Tyne, United Kingdom · Not yet recruiting

  • Liverpool University Hospitals NHS Foundation Trust - Royal Liverpool University Hospital

    Liverpool, Merseyside, United Kingdom · Not yet recruiting

  • Northern Ireland Clinical Research Facility (NICRF) Solo/Group Practice

    Belfast, Northern Ireland, United Kingdom · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.